drugset / Trial / NCT00274638

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

NCT00274638

Phase 4 Completed 805 enrolled Boehringer Ingelheim
RandomizedParallel-groupOpen-labelTreatment

Summary

To demonstrate that Telmisartan combined with Hydrochlorothiazide (MICARDIS® HCT) is superior to Losartan with Hydrochlorothiazide (Hyzaar®) in lowering blood pressure in mild-moderate hypertensives.

Timeline

Start
2002-07
Primary completion
2003-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Losartan Other / unclassified 50 mg
Subject Telmisartan Other / unclassified 40 mg
Subject Telmisartan Other / unclassified 80 mg
Background Hydrochlorothiazide Unknown 12.5 mg

Indications